clinical trial · NCT02753127
A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer
Sumitomo Pharma America, Inc.·phase3·completed·n = 1,253
Colorectal CancerNapabucasinFluorouracilLeucovorinIrinotecanBevacizumab
brief summary
This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).
started
Jun 1, 2016
primary completion
Apr 28, 2020
completion
May 12, 2021
last updated
Nov 15, 2023
official title
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol